Consolidated revenue for Q1 was 49,066 million yen, up 24.1% YoY. Operating profit was 12,311 million yen, up 23.4% YoY. Net income attributable to owners of the parent was 10,109 million yen, up 22.5% YoY. Full-year guidance unchanged. Segment-wise, Pharmaceuticals contributed 43,256 million yen in revenue and Functional Foods 5,810 million yen. A results briefing is scheduled.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4516","jir_company_name":"Nihon Shinyaku Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4516-20260806-01.pdf","jir_short_summary":"Consolidated revenue for Q1 was 49,066 million yen, up 24.1% YoY. Operating profit was 12,311 million yen, up 23.4% YoY. Net income attributable to owners of the parent was 10,109 million yen, up 22.5% YoY. Full-year guidance unchanged. Segment-wise, Pharmaceuticals contributed 43,256 million yen in revenue and Functional Foods 5,810 million yen. A results briefing is scheduled.","jir_summary":"### Overview of results\nThis quarter's revenue was 49,066 million yen, up 24.1% YoY, primarily supported by continued growth in Utarabi, Fintepla, Jaiparka, etc., despite price revisions and generic impact, with contribution from Uptra. Operating profit was 12,311 million yen, up 22.1% YoY; income before tax was 12,959 million yen; quarterly net income was 10,108\u201310,109 million yen (interim disclosed value is 10,109 million yen, up 22.5% YoY). Pharmaceutical and Functional Foods sales remained solid. Full-year guidance unchanged from prior disclosure.\n\n### Outlook and key notes\nSupplementary materials for the results are available; a conference call for institutional investors and securities analysts will be held. There are no changes to the full-year business forecast for fiscal year ending March 2027. Segment details: Pharmaceuticals revenue 43,256 million yen, Functional Foods 5,810 million yen. For new drug development, progress in multiple Phase III\/PP trials and the impact of license agreements are noted, and future clinical\/approval trends may affect results.","jir_financial_highlights":"Revenue: 49,066 (YoY +24.1%)\nOperating profit: 12,311 (YoY +22.1%)\nIncome before tax for the quarter: 12,959 (YoY +23.4%)\nNet income attributable to owners of the parent: 10,109 (YoY +22.5%)\nBasic earnings per share for the quarter: 149.98 (YoY)","jir_category":"","jir_hashtags":"#NihonShinyaku, #Results, #Q1FinancialSummary, #PharmaceuticalsBusiness, #FunctionalFoodsBusiness","jir_key_figures":"Revenue: 49,066 million yen (YoY +24.1%)\nOperating profit: 12,311 million yen (YoY +22.1%)\nNet income attributable to owners of the parent: 10,109 million yen (YoY +22.5%)","jir_meta_title":"\u3010Nihon Shinyaku Co., Ltd.\u3011Q1 Financial Summary (IFRS) (Consolidated) for Fiscal Year Ending 2027","jir_meta_description":"Key points of Nihon Shinyaku's Q1 FY2027 financial results. Revenue 49,066 million yen, operating profit 12,311 million yen, YoY growth. Full-year forecast unchanged. Segment details for Pharmaceuticals and Functional Foods and notable upcoming points.","jir_og_title":"Nihon Shinyaku Q1 Financial Summary Highlights","jir_og_description":"Nihon Shinyaku Q1 results show revenue of 49,066 million yen and operating profit of 12,311 million yen. Full-year forecast unchanged. Summary of segment trends in Pharmaceuticals and Functional Foods.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7976,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-96117","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n